Gujarat Themis Biosyn Q3 Results: Net Profit Declines to ₹1,246.46 Lakhs
Gujarat Themis Biosyn reported Q3 net profit of ₹1,246.46 lakhs, down from ₹1,297.23 lakhs YoY. Nine-month profit was ₹3,579.03 lakhs, down from ₹3,677.35 lakhs. Ms. Kirandeep Madan was re-appointed as Independent Director. Mr. Krupesh Patel appointed as CFO from April 1, 2026.
The decline in profit and changes in key management positions can have a moderate impact on investor sentiment and company operations.
The net profit for the quarter and the nine-month period has declined compared to the previous year.
Gujarat Themis Biosyn Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a net profit of ₹1,246.46 lakhs for the quarter, a decrease compared to ₹1,297.23 lakhs in the same period last year. For the nine-month period, net profit stood at ₹3,579.03 lakhs, down from ₹3,677.35 lakhs in the corresponding period of the previous fiscal year.
During the board meeting held on February 5, 2026, the re-appointment of Ms. Kirandeep Madan as Non-Executive Woman Independent Director for a second term from May 1, 2026, to April 30, 2031, was approved, subject to shareholder approval. Additionally, Mr. Bhavik Shah will transition from his role as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) effective April 1, 2026, to focus on plant-related accounting activities. Mr. Krupesh Patel has been appointed as the new CFO and KMP, effective April 1, 2026.
The company also reported an incremental impact of ₹13.36 lakhs due to the new Labour Codes notified by the Government of India.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.